HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch
Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year.
Coverage brought to you by











.png)